A young adult female Mastiff dog developed a large retroperitoneal mass, pleural effusion, and multiple pulmonary and pleural nodules. All masses were diagnosed as mesenchymal subtype chondrosarcomas, using histological and immunohistochemical criteria. Reports of canine extraskeletal mesenchymal chondrosarcomas (EMCs) are rare but involved animals less than 3 years of age in 60% of the cases. This is the first description of this type of tumor developing distant metastases. Evidence from this case and previous reports suggests that EMCs are associated with a poor prognosis.
trally placed nuclei that contained indistinct nucleoli. Cytoplasm was scant and faintly eosinophilic. Cells within the second neoplastic cell pattern were arranged in whorls and bundles. The cells were larger, more elongated, and contained a centrally placed nucleus with marginated chromatin and prominent, often multiple nucleoli. The cells contained moderate quantities of faintly basophilic cytoplasm. Numerous binucleate cells, frequent multinucleate cells, and 3 mitotic figures per 400ϫ field were visible within the neoplastic cell population. Multiple foci of poorly formed cartilage were visible throughout the tumor (Fig. 2) , especially within areas that contained larger, more spindloid cells. No osteoid formation was visible within the tumor. Multiple areas of necrosis were present throughout the neoplasm. These areas contained cell debris that was occasionally mineralized, degenerate and nondegenerate neutrophils, and hemosiderinladen macrophages. Sections of lung revealed mild alveolar collapse, with numerous variably sized nodules of neoplastic cells within the parenchyma of the lung, pleura, and lymphatics ( Fig. 3 ). Neoplastic cells within the metastatic foci appeared similar to the cells within the retroperitoneal mass, but a higher proportion were round, and few areas of cartilaginous differentiation were visible. The pleura were diffusely thickened by fibrous tissue and marked mesothelial cell hyperplasia.
Immunohistochemically, approximately 95% of the neoplastic cells demonstrated cytoplasmic immunoreactivity with antibodies against vimentin ( Fig. 4) , and approximately 20% of the cells reacted with antibodies against S-100 protein ( Fig. 5 ). Cells within the retroperitoneal and pulmonary masses exhibited similar staining characteristics. Cells did not react with desmin, cytokeratin, or smooth muscle actin antibodies.
Chondrosarcomas are classified as skeletal or extraskeletal. The most common sites for canine skeletal chondrosarcomas are the nasal cavity, ribs, and pelvis. 4 Approximately 1% of canine chondrosarcomas develop in an extraskeletal location, 12 such as the omentum, 12 lung, 12 mitral leaflet, 12 caudal abdomen, 13 atrium, 1 and aorta. 3 Chondrosarcomas are further classified by the appearance of the neoplastic cells. Conventional chondrosarcomas contain spindloid cells that form, and are trapped within, a basophilic, hyaline matrix. 2 Mesenchymal chondrosarcomas are the second most frequently reported canine chondrosarcoma subtype. 10 As described in the present case, these tu- mors consist of areas that contain poorly differentiated round-to-oval cells arranged in sheets, as well as areas that resemble a conventional chondrosarcoma. In dogs, mesenchymal chondrosarcomas develop most frequently in the sinonasal bones and are the most common chondrosarcoma subtype in this location. 10 They have also been reported in the ribs. 10 The myxoid variant, the least commonly reported canine chondrosarcoma subtype, 9 appears as lobules of myxoid stroma containing islands of collagen and cartilage. 9 Of the 6 extraskeletal chondrosarcomas reported previously in the veterinary literature, 4 (caudal abdominal, 13 pulmonary, 12 omental, 12 and atrial 1 ) had histologic characteristics consistent with mesenchymal subtypes. The other 2 were consistent with conventional chondrosarcomas. Within the human literature, most extraskeletal chondrosarcomas are of the myxoid or mesenchymal types. 6 A recent review of 513 human chondrosarcomas reported 9 extraskeletal tumors, of which 4 were mesenchymal and 5 were myxoid. 5 In human medicine, differentiation between these 2 subtypes is vital because metastases are reported in 50%-100% of extraskeletal mesenchymal tumors compared with 0%-20% in extraskeletal myxoid subtypes. 5 Approximately 30% of human mesenchymal chondrosarcomas develop in extraskeletal locations, 8 but only 5 retroperitoneal mesenchymal chondrosarcomas have been reported. 7 Human extraskeletal mesenchymal chondrosarcomas (EMCs) most frequently develop in the second or third decades of life. 11 Including the currently described case, 3 of the 5 reported cases of canine EMC were in animals less than 3 years of age. 1, 13 This suggests that, as in humans, canine EMCs may develop more frequently in animals considered to be young adults.
Human EMCs have a mean time to metastasis of 10 months, most commonly to the lungs. 5, 11 Although local invasion was reported in 1 case of canine EMC, 12 distant metastases have not been reported within the veterinary literature. 1, 12, 13 As in the present case, all 4 previously reported cases of canine EMC were euthanitized at the time of diagnosis. 1, 12, 13 Immunohistochemical staining in this case revealed widespread vimentin expression, whereas only a proportion of cells contained S-100 protein. These findings are consistent with those reported for human mesenchymal chondrosarcomas. 8 Ultrastructural studies on human tumors revealed that S-100 protein expression was confined to cells with chondroblastic organelles. 8 Cells that did not react with S-100 protein antibodies were considered less differentiated and consistent with embryonal chondrocytes. 8 This partial S-100 protein immunoreactivity is an important feature in tumors without visible cartilage formation because it allows differentiation from other poorly differentiated round cell sarco-mas, such as rhabdomyosarcoma, peripheral neuroepithelioma, and synovial sarcoma. 8 In conclusion, this is the first report of a canine retroperitoneal EMC and the first tumor of this type with distant metastases. Evidence from this case suggests that canine EMCs may follow a clinical pattern similar to that of their human counterparts. Patients should be evaluated for pulmonary metastasis if such a tumor develops. Findings in this case and from the few previous reports suggest that a poor prognosis is associated with these tumors.
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